Has Thyrogen been studied in children or adolescents?
Recombinant TSH safety and levels of TSH following Thyrogen administration have been examined in a retroespctive study of 100 patients 5-18 years of age in a multi-center study of young subjects with thyroid cancer. This was not a head to head analysis of rTSH vs. withdrawal. Most patients were administered the drug for diagnostic purposes (61%), some for therapeutic remnant ablation (18%) or treatment of more advanced disease (20%). Nausea and vomiting were the most common adverse events and occurred in less than 55 of subjects. The majority of patients achieved a peak TSH of more than 25 mU/L. The drug appears to be relatively well tolerated and useful in this patient population. J Clin Endocrinol Metab. 2009 Oct;94(10):3948-53. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.
